Expert Outlook: TransMedics Gr Through The Eyes Of 7 Analysts
Portfolio Pulse from Benzinga Insights
In the past three months, 7 analysts have provided ratings for TransMedics Group (NASDAQ:TMDX), with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased by 21.86% to $123.57. Analysts have raised their price targets, reflecting positive expectations for the company's future performance.
June 04, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TransMedics Group (NASDAQ:TMDX) has received predominantly bullish ratings from analysts, with an average 12-month price target increase of 21.86% to $123.57. Analysts have raised their price targets, indicating positive expectations for the company's future performance.
The increase in the average price target and the predominantly bullish ratings from multiple analysts suggest a positive short-term impact on TMDX's stock price. The raised price targets reflect analysts' confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100